September 24th, 2019NMPA accepts our filing for TENELIA,a treatment agent for type 2 diabetes mellitus in China
Mitsubishi Tanabe Pharma Corporation (MTPC) (Head Office: Chuo-ku, Osaka;
President & Representative Director, CEO: Masayuki Mitsuka), announced today that
the National Medical Products Administration (NMPA) accepted MTPC's filing throughMitsubishi Tanabe Pharma Development (Beijing) Co., Ltd., which is MTPC's R&D
subsidiary in China for TENELIA (generic name: teneligliptin hydrobromide hydrate;
Japan name: TENELIA® 20 mg tablets), a treatment agent for type 2 diabetes
mellitus.
TENELIA®, originating in Japan, is a dipeptidyl peptidase-4 (DPP-4) inhibitor
discovered by MTPC. TENELIA® has made it highly effective in lowering each of the
postprandial blood glucose levels, as well as fasting blood glucose levels, withonce-a-day administration. TENELIA® needs no dose adjustments according to thelevels of renal or hepatic dysfunction, so that TENELIA® can be used to treat a wide
range of patients with diabetes.
China has about 120 million people with diabetes* (as of 2017), the largest in theworld, and China accounts for approximately 30% of the total number of worldwide
patients with diabetes. This proportion is expected to continue increasing.
Tianjin Tanabe Seiyaku Co., Ltd. (Tianjin Tanabe), MTPC's manufacturing and sales
subsidiary in China, has concluded a strategic agreement to promote TENELIA® with
Servier (Tianjin) Pharmaceutical Co., Ltd. (Servier Tianjin) in February 2019. In
collaboration with Servier Tianjin, which in China has approximately 700 medical
representatives (MRs) specializing in diabetes, Tianjin Tanabe will contribute to earlymarket penetration and product value maximization of TENELIA®.
By providing a new option for the treatment of diabetes in China, the second largest
pharmaceutical market in the world, MTPC shows its continued resolve to help
patients in China.
Source: International Diabetes Federation (IDF)*

Mitsubishi Tanabe Pharma Corporation
Corporate Communications Department
Media contacts: TEL: +81 6 6205 5119
Investor contacts: TEL: +81 6 6205 5110

1/2

<Reference>■ About TENELIA
In Japan, approval for TENELIA (generic name: teneligliptin hydrobromide hydrate,
Japan name: TENELIA® 20 mg tablets), a treatment agent for type 2 diabetes mellitus,
was received in June 2012, with approval for a partial change in its indication received
in December 2013. In Korea, approval for use of TENELIA in combination withbiguanide agents was received in April 2014. Development of TENELIA is being
promoted not only in China, where application has just been filed, but also in other
ASEAN countries.

■ About Mitsubishi Tanabe Pharma Development (Beijing) Co., Ltd.
Mitsubishi Tanabe Pharma Development (Beijing) Co., Ltd. is a wholly-owned
subsidiary founded by MTPC in Beijing, China, in 2006. The company is engaged inself-promoted clinical development aimed at receiving marketing approval ofpharmaceuticals in China. As a key base of the MTPC group in China, it promotes
business in China by developing new drugs and receiving their approval in thecountry, thereby seeking to enhance MTPC's corporate value.

■ About Tianjin Tanabe Seiyaku Co., Ltd.
Tianjin Tanabe Seiyaku Co., Ltd. was founded in Tianjin, China, in 1993 through joint
financing from Tianjin Lisheng Pharmaceutical Co., Ltd. and MTPC. The company isengaged in the manufacture and sales of pharmaceuticals in China. As a corecompany of the MTPC group in China, the company seeks to contribute to medical
needs in China through the manufacture and sales of high quality pharmaceuticals
with the MTPC brand, particularly cardiovascular drugs, gastrointestinal drugs, andanti-allergic agents for patients in China.

2/2